Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

被引：27

作者：

Yasin, Ayse Irem ^{[1
]}

Aydin, Sabin Goktas ^{[2
]}

Sumbul, Bilge ^{[3
]}

Koral, Lokman ^{[4
]}

Simsek, Melih ^{[1
]}

Geredeli, Caglayan ^{[5
]}

Ozturk, Akin ^{[6
]}

Perkin, Perihan ^{[7
]}

Demirtas, Derya ^{[8
]}

Erdemoglu, Engin ^{[9
]}

Hacibekiroglu, Ilhan ^{[10
]}

Cakir, Emre ^{[10
]}

Tanrikulu, Eda ^{[11
]}

Coban, Ezgi ^{[11
]}

Ozcelik, Melike ^{[12
]}

Celik, Sinemis ^{[13
]}

Teker, Fatih ^{[14
]}

Aksoy, Asude ^{[15
]}

Firat, Sedat T. ^{[16
]}

Tekin, Omer ^{[17
]}

Kalkan, Ziya ^{[18
]}

Turken, Orhan ^{[19
]}

Oven, Bala B. ^{[20
]}

Dane, Faysal ^{[21
]}

Bilici, Ahmet ^{[2
]}

Isikdogan, Abdurrahman ^{[18
]}

Seker, Mesut ^{[1
]}

Turk, Haci M. ^{[1
]}

Gumus, Mahmut ^{[9
]}

机构：

[1] Bezmialem Vakif Univ, Dept Med Oncol, TR-34093 Istanbul, Turkey

[2] Medipol Univ, Dept Med Oncol, TR-34214 Istanbul, Turkey

[3] Bezmialem Vakif Univ, Dept Microbiol, TR-34093 Istanbul, Turkey

[4] Canakkale 18 March Univ, Dept Med Oncol, TR-17020 Canakkale, Turkey

[5] 0Kmeydani Training & Res Hosp, Dept Med Oncol, TR-34384 Istanbul, Turkey

[6] SureyyapasaChest Dis & Thorac Surg Training & Res, Dept Med Oncol, TR-34844 Istanbul, Turkey

[7] Yildirim Beyazit Univ, Dept Med Oncol, Yenimahalle Training & Res Hosp, TR-06330 Ankara, Turkey

[8] AnkaraCity Hosp, Dept Med Oncol, TR-06800 Ankara, Turkey

[9] GoztepeMedeniyet Univ, Dept Med Oncol, TR-34000 Istanbul, Turkey

[10] Sakarya Univ, Dept Med Oncol, Med Fac, TR-54050 Sakarya, Turkey

[11] Univ Hlth Sci, Haydarpasa Training & Res Hosp, TR-34668 Istanbul, Turkey

[12] Marmara Univ, Dept Med Oncol, Sch Med, TR-34722 Istanbul, Turkey

[13] Istanbul Oncol Hosp, Dept Med Oncol, TR-34846 Istanbul, Turkey

[14] Gaziantep Univ, Dept Med Oncol, TR-27470 Gaziantep, Turkey

[15] Firat Univ, Dept Med Oncol, Fac Med, TR-23119 Elazig, Turkey

[16] Erciyes Univ, Dept Med Oncol, TR-38039 Kayseri, Turkey

[17] Inonu Univ, Dept Med Oncol, TR-44280 Malatya, Turkey

[18] Dicle Univ, Dept Med Oncol, TR-21200 Diyarbakir, Turkey

[19] MaltepeUniv, Dept Med Oncol, TR-34844 Istanbul, Turkey

[20] Bahcesehir Univ, Dept Med Oncol, Sch Med, TR-34349 Istanbul, Turkey

[21] Acibadem Univ, Dept Med Oncol, TR-34758 Istanbul, Turkey

来源：

FUTURE ONCOLOGY | 2022年 / 18卷 / 10期

关键词：

cancer; chemotherapy; CoronaVac; COVID-19; vaccines; immunotherapy; malignancy; SARS-CoV-2;

D O I：

10.2217/fon-2021-1248

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: To compare the seropositivity rate of cancer patients with non-cancer controls after inactive SARS-CoV-2 vaccination (CoronaVac) and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 non-cancer volunteers. An IgG level >= 50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients. Clinical Trials Registration: ClinicalTrials.gov) Plain language summary Cancer patients are at high risk for infection with SARS-CoV-2 and of developing the associated disease, COVID-19, which therefore puts them in the priority group for vaccination. This study evaluated the efficacy and safety of CoronaVac, an inactivated virus vaccine, in cancer patients. The immune response rate, defined as seropositivity, was 85.2% in the cancer patient group and 97.5% in the control group. The levels of antibodies, which are blood markers of immune response to the vaccine, were also significantly lower in the patient group, especially in those older than 60 years and receiving chemotherapy. These results highlight the importance of determining the effective vaccine type and dose in cancer patients to protect them from COVID-19 without disrupting their cancer treatment.

引用

页码：1235 / 1244

页数：10

共 29 条

[1]

Abbott, SARS COV 2 IMMN

[2] Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy [J].

Ariamanesh, Mona ;

Porouhan, Pejman ;

PeyroShabany, Babak ;

Fazilat-Panah, Danial ;

Dehghani, Mansoureh ;

Nabavifard, Maryam ;

Hatami, Farbod ;

Fereidouni, Mohammad ;

Welsh, James S. ;

Javadinia, Seyed Alireza .

CANCER INVESTIGATION, 2022, 40 (01) :26-34

[3] COVID-19 and Cancer: Current Challenges and Perspectives [J].

Bakouny, Ziad ;

Hawley, Jessica E. ;

Choueiri, Toni K. ;

Peters, Solange ;

Rini, Brian, I ;

Warner, Jeremy L. ;

Painter, Corrie A. .

CANCER CELL, 2020, 38 (05) :629-646

[4]

Diabetomics Inc., 2021, ADVISEDX SARS COV 2

[5] Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study [J].

Fillmore, Nathanael R. ;

La, Jennifer ;

Szalat, Raphael E. ;

Tuck, David P. ;

Vinh Nguyen ;

Yildirim, Cenk ;

Do, Nhan, V ;

Brophy, Mary T. ;

Munshi, Nikhil C. .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (06) :691-698

[6] SARS-CoV-2 testing for asymptomatic adult cancer patients before initiating systemic treatments: a systematic review [J].

Harada, Guilherme ;

Antonacio, Fernanda F. ;

Gongora, Aline Bl ;

Behar, Marina H. ;

Capareli, Fernanda C. ;

Bastos, Diogo A. ;

Munhoz, Rodrigo R. ;

Costa, Frederico P. ;

Jardin, Denis L. ;

Arrais-Rodrigues, Celso ;

Novis, Yana ;

Katz, Artur ;

de Castro Junior, Gilberto .

ECANCERMEDICALSCIENCE, 2020, 14

[7] Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection [J].

Harvey, Raymond A. ;

Rassen, Jeremy A. ;

Kabelac, Carly A. ;

Turenne, Wendy ;

Leonard, Sandy ;

Klesh, Reyna ;

Meyer, William A., III ;

Kaufman, Harvey W. ;

Anderson, Steve ;

Cohen, Oren ;

Petkov, Valentina I. ;

Cronin, Kathy A. ;

Van Dyke, Alison L. ;

Lowy, Douglas R. ;

Sharpless, Norman E. ;

Penberthy, Lynne T. .

JAMA INTERNAL MEDICINE, 2021, 181 (05) :672-679

[8] Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need [J].

Jin, Pengfei ;

Li, Jingxin ;

Pan, Hongxing ;

Wu, Yanfei ;

Zhu, Fengcai .

SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)

[9] SARS-CoV-2 vaccines in development [J].

Krammer, Florian .

NATURE, 2020, 586 (7830) :516-527

[10] Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study [J].

Kuderer, Nicole M. ;

Choueiri, Toni K. ;

Shah, Dimpy P. ;

Shyr, Yu ;

Rubinstein, Samuel M. ;

Rivera, Donna R. ;

Shete, Sanjay ;

Hsu, Chih-Yuan ;

Desai, Aakash ;

Lopes, Gilberto de Lima, Jr. ;

Grivas, Petros ;

Painter, Corrie A. ;

Peters, Solange ;

Thompson, Michael A. ;

Bakouny, Ziad ;

Batist, Gerald ;

Bekaii-Saab, Tanios ;

Bilen, Mehmet A. ;

Bouganim, Nathaniel ;

Larroya, Mateo Bover ;

Castellano, Daniel ;

Del Prete, Salvatore A. ;

Doroshow, Deborah B. ;

Egan, Pamela C. ;

Elkrief, Arielle ;

Farmakiotis, Dimitrios ;

Flora, Daniel ;

Galsky, Matthew D. ;

Glover, Michael J. ;

Griffiths, Elizabeth A. ;

Gulati, Anthony P. ;

Gupta, Shilpa ;

Hafez, Navid ;

Halfdanarson, Thorvardur R. ;

Hawley, Jessica E. ;

Hsu, Emily ;

Kasi, Anup ;

Khaki, Ali R. ;

Lemmon, Christopher A. ;

Lewis, Colleen ;

Logan, Barbara ;

Masters, Tyler ;

McKay, Rana R. ;

Mesa, Ruben A. ;

Morgans, Alicia K. ;

Mulcahy, Mary F. ;

Panagiotou, Orestis A. ;

Peddi, Prakash ;

Pennell, Nathan A. ;

Reynolds, Kerry .

LANCET, 2020, 395 (10241) :1907-1918

← 1 2 3 →